Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, shared a post on X/Twitter:
“Our work on plat-ineligibility in Metastatic Urothelial Carcinoma (mUC) and survival outcomes out in the Journal of the National Cancer Institute (JNCI).
- First, to provide quantitative benchmarks
- Only 11% of >4000 patients plat-ineligible
- Poor median overall survival ~5 months
We used our previously defined criteria for plat-ineligibility. Unmet need to develop novel trials in plat-ineligible mUC patients. Ongoing trial of Anti-LAG/TIGIT/PD-L1 will help provide further insights. Enrolling globally. Available here.”
Source: Shilpa Gupta/X
